Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Made Gains In Oncology, Though Virology Remains King

New Studies And Catalysts For Trodelvy And Magrolimab Anticipated In 2021

Executive Summary

Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.

You may also be interested in...



Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy

Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.

Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries

Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.

Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel